{"component": "definition", "props": {"groups": [{"snippet": "means the field of prevention, palliation, control or treatment in humans of (a) depression, schizophrenia, bipolar disease, dementia, anxiety, attention deficit hyperactivity disorder, anorexia nervosa and other affective disorders, (b) Alzheimer\u2019s disease and other cognitive disorders, (c) P\u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2019\u2587 disease, amyotrophic lateral sclerosis and other neurodegenerative disorders, (d) pain, (e) epilepsy, (f) insomnia, narcolepsy and other sleep disorders, (g) substance abuse and (h) migraine.", "snippet_links": [{"key": "field-of", "type": "definition", "offset": [10, 18]}, {"key": "amyotrophic-lateral-sclerosis", "type": "definition", "offset": [314, 343]}, {"key": "sleep-disorders", "type": "clause", "offset": [442, 457]}, {"key": "substance-abuse", "type": "clause", "offset": [463, 478]}], "size": 5, "samples": [{"hash": "l0olhV81VpG", "uri": "/contracts/l0olhV81VpG#cns-field", "label": "Technology License Agreement (Lexicon Pharmaceuticals, Inc./De)", "score": 21.0, "published": true}, {"hash": "9U5jRIhbKFz", "uri": "/contracts/9U5jRIhbKFz#cns-field", "label": "Research and Development Agreement (Lexicon Pharmaceuticals, Inc./De)", "score": 21.0, "published": true}, {"hash": "7luI0O2G9RG", "uri": "/contracts/7luI0O2G9RG#cns-field", "label": "Purchase Option Agreement (Lexicon Pharmaceuticals, Inc./De)", "score": 21.0, "published": true}], "hash": "0534b8a0303208678d746910ed1baf7e", "id": 1}, {"snippet": "means use in the following indications: [***], in each case in humans, using any delivery modality.", "snippet_links": [{"key": "each-case", "type": "definition", "offset": [50, 59]}], "size": 4, "samples": [{"hash": "e7Z7WxhFecw", "uri": "/contracts/e7Z7WxhFecw#cns-field", "label": "Development and Commercialization Agreement (Mesoblast LTD)", "score": 26.7193702943, "published": true}, {"hash": "hgoBviDMJyR", "uri": "/contracts/hgoBviDMJyR#cns-field", "label": "Development and Commercialization Agreement (Mesoblast LTD)", "score": 25.93908282, "published": true}, {"hash": "6vcTQ4P0d4o", "uri": "https://investorsmedia.mesoblast.com/static-files/0a4018e2-9517-43cb-81ed-5f26c37d87f4", "label": "investorsmedia.mesoblast.com", "score": 9.9623545517, "published": false}], "hash": "d51407982c74f5d92fc100d9dffd1acc", "id": 2}, {"snippet": "means the treatment or prevention of CNS diseases or disorders in humans.", "snippet_links": [{"key": "cns-diseases", "type": "definition", "offset": [37, 49]}], "size": 4, "samples": [{"hash": "jvfS69kfJn9", "uri": "/contracts/jvfS69kfJn9#cns-field", "label": "Collaboration Agreement (Signal Pharmaceuticals Inc)", "score": 18.0, "published": true}, {"hash": "giSqvHY3mFf", "uri": "/contracts/giSqvHY3mFf#cns-field", "label": "Collaboration Agreement (Signal Pharmaceuticals Inc)", "score": 18.0, "published": true}, {"hash": "1Yba19AtI2u", "uri": "/contracts/1Yba19AtI2u#cns-field", "label": "Collaboration Agreement (Signal Pharmaceuticals Inc)", "score": 18.0, "published": true}], "hash": "b7327a68d012c3095762b985c77d3920", "id": 3}, {"snippet": "means [***].", "snippet_links": [], "size": 3, "samples": [{"hash": "cwnrEaZTqM2", "uri": "/contracts/cwnrEaZTqM2#cns-field", "label": "Option and Collaboration Agreement (Denali Therapeutics Inc.)", "score": 29.5284052019, "published": true}, {"hash": "k5x8fWTAhZj", "uri": "/contracts/k5x8fWTAhZj#cns-field", "label": "Option and Collaboration Agreement (Denali Therapeutics Inc.)", "score": 29.2108145106, "published": true}, {"hash": "hJQ8BscgL7g", "uri": "http://investors.denalitherapeutics.com/static-files/7d466fef-45dc-46bc-b2ef-d5cafecd94da", "label": "Amendment", "score": 14.1704312115, "published": false}], "hash": "42145ccc68badf480a8ed917c57dd5fc", "id": 4}, {"snippet": "means only the functionality within the applicable product that conforms to or practices all or any part of the Legacy Wi-Fi Standard. For clarity, CNS Field excludes the functionality within the applicable product that conforms to or practices all or any part of the Wi-Fi 6 Standard and/or any other IEEE 802.11 standard published thereafter.", "snippet_links": [{"key": "applicable-product", "type": "definition", "offset": [40, 58]}, {"key": "for-clarity", "type": "clause", "offset": [135, 146]}], "size": 3, "samples": [{"hash": "l9bL6edXZZB", "uri": "/contracts/l9bL6edXZZB#cns-field", "label": "Sublicense Agreement", "score": 35.2863132229, "published": true}, {"hash": "2uZ8oXNuW8r", "uri": "/contracts/2uZ8oXNuW8r#cns-field", "label": "Sublicense Agreement", "score": 28.1485284052, "published": true}, {"hash": "hpm8zokyOdD", "uri": "/contracts/hpm8zokyOdD#cns-field", "label": "Sublicense Agreement", "score": 27.4681724846, "published": true}], "hash": "e787f6d60004884485d2f383f4b586d6", "id": 5}, {"snippet": "means delivery of drugs for the treatment of --------- pain, [* * *] directly into a component of the central nervous system from an implantable pump via a catheter; provided, however, solely with respect to a Product using Sufentanil as the Drug, there shall be no requirement that the Drug be delivered via a catheter.", "snippet_links": [{"key": "delivery-of", "type": "clause", "offset": [6, 17]}, {"key": "treatment-of", "type": "definition", "offset": [32, 44]}, {"key": "central-nervous-system", "type": "definition", "offset": [102, 124]}, {"key": "with-respect-to", "type": "clause", "offset": [192, 207]}, {"key": "no-requirement", "type": "clause", "offset": [263, 277]}], "size": 3, "samples": [{"hash": "ggjwrKaE97a", "uri": "/contracts/ggjwrKaE97a#cns-field", "label": "Development and Commercialization Agreement (Durect Corp)", "score": 18.0, "published": true}, {"hash": "1HgLfWbYFfo", "uri": "/contracts/1HgLfWbYFfo#cns-field", "label": "Development and Commercialization Agreement (Durect Corp)", "score": 18.0, "published": true}], "hash": "4417175eb8d941d6252bb0e7c0aef83a", "id": 6}, {"snippet": "means diseases of the central nervous system.", "snippet_links": [{"key": "central-nervous-system", "type": "definition", "offset": [22, 44]}], "size": 2, "samples": [{"hash": "2JLP4lIMeiK", "uri": "/contracts/2JLP4lIMeiK#cns-field", "label": "Exclusive License Agreement (Vigil Neuroscience, Inc.)", "score": 32.8822724162, "published": true}, {"hash": "aaH3n6BAqVl", "uri": "/contracts/aaH3n6BAqVl#cns-field", "label": "Exclusive License Agreement (Vigil Neuroscience, Inc.)", "score": 32.7672826831, "published": true}], "hash": "a3afc9bcb03954f82c49a879b308739e", "id": 7}, {"snippet": "means the central nervous system (\u201cCNS\u201d) and/or cerebrocardiovascular drug application, including the (preventive) treatment of peripheral of effects of agents causing CNS disease or symptoms.", "snippet_links": [{"key": "central-nervous-system", "type": "definition", "offset": [10, 32]}, {"key": "drug-application", "type": "definition", "offset": [70, 86]}, {"key": "treatment-of", "type": "definition", "offset": [115, 127]}], "size": 2, "samples": [{"hash": "epy52YRAzWi", "uri": "/contracts/epy52YRAzWi#cns-field", "label": "Exclusive License Agreement (Allarity Therapeutics, Inc.)", "score": 32.794661191, "published": true}, {"hash": "1tp21hqHLof", "uri": "/contracts/1tp21hqHLof#cns-field", "label": "Exclusive License Agreement (Allarity Therapeutics, Inc.)", "score": 32.6331279945, "published": true}], "hash": "78112e990d4b125d11a15af5b7df92c3", "id": 8}, {"snippet": "means the Exploitation of therapeutic compounds to treat, ameliorate or prevent CNS Diseases (and Diagnostics to the extent intended for use in connection with such therapeutic compounds).", "snippet_links": [{"key": "cns-diseases", "type": "definition", "offset": [80, 92]}, {"key": "to-the-extent", "type": "clause", "offset": [110, 123]}, {"key": "intended-for-use", "type": "definition", "offset": [124, 140]}, {"key": "in-connection-with", "type": "clause", "offset": [141, 159]}], "size": 2, "samples": [{"hash": "exAkl3OVV7g", "uri": "/contracts/exAkl3OVV7g#cns-field", "label": "Research Collaboration and License Agreement (Neumora Therapeutics, Inc.)", "score": 34.6454483231, "published": true}, {"hash": "8aRBj20BDbo", "uri": "/contracts/8aRBj20BDbo#cns-field", "label": "Research Collaboration and License Agreement (Neumora Therapeutics, Inc.)", "score": 33.1204654346, "published": true}], "hash": "e0eafd1e82bf55a8b635468b23b21b43", "id": 9}, {"snippet": "means (a) the field of CNS Monogenic Rare Disorders, (b) Alzheimer\u2019s Disease and Temporal Lobe Epilepsy, and (c) any other available non-monogenic and/or non-rare CNS indications that the Parties may mutually agree to include in the CNS Field [*] (the disorders under subsections", "snippet_links": [{"key": "field-of", "type": "definition", "offset": [14, 22]}, {"key": "the-parties", "type": "clause", "offset": [184, 195]}, {"key": "agree-to", "type": "clause", "offset": [209, 217]}], "size": 1, "samples": [{"hash": "7i3ARq64kdl", "uri": "https://s27.q4cdn.com/477254652/files/doc_financials/2021/q3/b923c8ac-1485-4b9b-a39c-06226f77cb69.pdf", "label": "s27.q4cdn.com", "score": 9.1861738535, "published": false}], "hash": "e81222039784ce99cbac726e40d96ef1", "id": 10}], "next_curs": "ClYSUGoVc35sYXdpbnNpZGVyY29udHJhY3RzcjILEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiISY25zLWZpZWxkIzAwMDAwMDBhDKIBAmVuGAAgAA==", "definition": {"snippet": "means the field of prevention, palliation, control or treatment in humans of (a) depression, schizophrenia, bipolar disease, dementia, anxiety, attention deficit hyperactivity disorder, anorexia nervosa and other affective disorders, (b) Alzheimer\u2019s disease and other cognitive disorders, (c) P\u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2019\u2587 disease, amyotrophic lateral sclerosis and other neurodegenerative disorders, (d) pain, (e) epilepsy, (f) insomnia, narcolepsy and other sleep disorders, (g) substance abuse and (h) migraine.", "title": "CNS Field", "size": 35, "id": "cns-field", "examples": ["The covenant in Section 2.3 does not include any waiver of accruing liability in the <strong>CNS Field</strong>.", "Eisai has not granted to any Person other than OV a license, covenant not to \u2587\u2587\u2587 or similar right with respect to any component of the Eisai Intellectual Property in the Field or the <strong>CNS Field</strong> in the Territory.", "This Agreement will commence upon the Effective Date and, except to the extent terminated pursuant to this ARTICLE XIII, shall continue in full force and effect on a Sub- Field-by-Sub-Field basis (i.e., for the Cardiovascular Field, <strong>CNS Field</strong> and Oncology Field) until none of Cephalon, its Affiliates or Marketing Partners is Developing or Commercializing a Product in the Territory in such Sub-Field.", "Subject to the terms of this Agreement, Amgen hereby grants to RBNC and its Affiliates an irrevocable (except pursuant to Section 12.6.1(a)), worldwide, sublicensable (in accordance with Section 4.2), fully paid-up, royalty-free license under \u2587\u2587\u2587\u2587\u2587\u2019s rights in and to the Amgen Collaboration IP to Exploit Therapeutic Compounds and Diagnostics in the <strong>CNS Field</strong>.", "Subject to \u2587\u2587\u2587\u2587\u2587\u2019s retained rights described in clause (a), Amgen will not practice, use or otherwise exploit the Collaboration IP for applications within the <strong>CNS Field</strong> until the expiration of the RBNC Exclusivity Period (as applicable to the Amgen Collaboration Patents, Joint Collaboration Patents, Joint Inventions, and Amgen Collaboration Know-How).", "This Agreement will commence upon the Effective Date and, except to the extent terminated pursuant to this ARTICLE XIII, shall continue in full force and effect on a Sub-Field-by-Sub-Field basis (i.e., for the Cardiovascular Field, <strong>CNS Field</strong> and Oncology Field) until none of Cephalon, its Affiliates or Marketing Partners is Developing or Commercializing a Product in the Territory in such Sub-Field.", "As of the Effective Date and to Eisai\u2019s Knowledge, the use, manufacture, marketing, sale, promotion, importation, distribution and commercialization of the Product in the Field or the <strong>CNS Field</strong> in the Territory does not infringe, violate or misappropriate the intellectual property rights of any Person.", "Without limiting the foregoing, the right of Angioblast to terminate the Agreement pursuant to this Section 13.3(b) shall expire upon the earlier to occur of (I) the [***] Clinical Trial for the CNS Product for use in the <strong>CNS Field</strong> pursuant to Section 4.3(a)(i) above is unsuccessful as determined by the JSC or (B) Initiation of a [***] Clinical Trial or [***] Clinical Trial as described in clause (ii) of this Section 13.3(b).", "As of the Effective Date and to the Knowledge of Eisai, Eisai has no reason to believe that any Person has infringed, violated or misappropriated any of the Eisai Intellectual Property in the Field or the <strong>CNS Field</strong> in the Territory.", "Subject to the terms of this Agreement, RBNC hereby grants to Amgen and its Affiliates an irrevocable (except pursuant to Section 12.6.1(c)), worldwide, sublicensable (in accordance with Section 4.2), fully paid-up, royalty-free license under RBNC\u2019s rights in and to the RBNC Collaboration IP to Exploit therapeutic compounds or biologics and diagnostics outside of the <strong>CNS Field</strong>."], "related": [["x-ray-field", "X-ray field", "X-ray field"], ["light-field", "Light field", "Light field"], ["licensed-field", "Licensed Field", "Licensed Field"], ["licensed-field-of-use", "Licensed Field of Use", "Licensed Field of Use"], ["field-of-use", "Field of Use", "Field of Use"]], "related_snippets": [], "updated": "2025-07-07T00:17:00+00:00"}, "json": true, "cursor": ""}}